FibriCheck offers a screening and monitoring application for irregular heart rhythms including atrial fibrillation. The company provides a mobile solution that measures the user's cardiac rhythm with a smartphone camera. It automatically shares the data with a healthcare professional to streamline diagnosis and treatment. The company was founded in 2014 and is based in Hasselt, Belgium.
FibriCheck's Product Videos
FibriCheck's Products & Differentiators
FibriCheck B2C model (Essential and Premium)
The FibriCheck consumer app is certified as a medical device. After signing in to a subscription model, FibriCheck customers can perform an unlimited amount of measurements on their smartphone to accurately detect cardiac arrhythmias. Measurements take 60 seconds and come with a detailed algorithmic analysis. Statistics over time are available. Users can send specific measurements to a medical expert for manual review (manual review standard included in the Premium subscription).
Research containing FibriCheck
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned FibriCheck in 3 CB Insights research briefs, most recently on Dec 14, 2022.
Expert Collections containing FibriCheck
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
FibriCheck is included in 2 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Latest FibriCheck News
Dec 1, 2023
Use your mobile to check for arrhythmia as Advanced Health Intelligence launches AF-Scan HealthTech company Advanced Health Intelligence (ASX: AHI) is set to launch a medically-approved mobile phone-based atrial fibrillation (AF) assessment in Q2 CY24 in collaboration with Belgium-based Qompium NV, a company specialising in mobile scanning tech. Globally, there are about 60 million cases of atrial fibrillation (AF), which is a form of arrhythmia involving irregular heartbeat. Despite its prevalence, its detection remains tricky, seeing as about 40% of patients are asymptomatic. AF can have dire consequences, increasing the risk of stroke five-fold—making it crucial to have a better detection solution in place. That’s where AHI’s new smartphone-based AF scan comes into play. The five-year agreement with Qompium NV expands its current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service. AHI will pay Qompium an initial cash fee for the right to access the AF Scan software, with another cash fee payable following the completion of the integration. Chief Innovation Officer at AHI, Dylan Garnett, said, “AF-Scan is a revolutionary addition to our Cardiac Health portfolio. This innovation comes at a critical time, as emerging research highlights novel AF risk factors, emphasising the importance of risk factor interventions in reducing AF incidence and managing episodes effectively. “AF-Scan is a groundbreaking mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide.” The AF scan uses Photoplethysmography (PPG) tech, which is non-invasive. A detector and light source on your skin detects subtle changes in blood vessels as your heart beats. This provides precise insights into your heart’s rhythm and overall health. AHI’s BHA uses your smartphone’s flashlight and camera to gather PPG data. It employs a certified AI algorithm to swiftly analyse this data, generating a user-friendly report for your physician. This report helps you and your doctor discuss and make informed decisions about your heart health. In a nutshell, AF-Scan’s PPG tech lets you conveniently monitor your heart rhythm with your smartphone for timely healthcare decisions. The application has been medically approved in Australia, USA, Singapore, EU, UK, UAE and Saudi Arabia for near clinical. The technology has received medical approval in multiple jurisdictions. AF currently affects 2-4% of the population, with a rising trend due to an increasing ageing population and subsequent detection efforts. Aging is a significant risk factor, along with comorbidities like hypertension and diabetes. Globally, the AF market is projected to surpass $72.7 billion by 2030. Besides its health concerns, AF also weighs heavily on healthcare systems and economies, costing institutions plenty in detection and treatment. AF Scan will assist in the screening identification dilemma of at-risk individuals, which is one of the most significant challenges associated with AF. The condition is notorious for being elusive and, at times, asymptomatic, making it challenging to identify in its early stages. Founder and Head of Strategy at AHI, Vlado Bosanac, said, “AHI will incorporate the AF-Scan into our biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. “This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing us to offer a holistic view of their well-being.” The Company did not mention potential revenue from this agreement.
FibriCheck Frequently Asked Questions (FAQ)
When was FibriCheck founded?
FibriCheck was founded in 2014.
Where is FibriCheck's headquarters?
FibriCheck's headquarters is located at Corda Campus Kempische Steenweg 303/27, Hasselt.
What is FibriCheck's latest funding round?
FibriCheck's latest funding round is Series A.
How much did FibriCheck raise?
FibriCheck raised a total of $11.46M.
Who are the investors of FibriCheck?
Investors of FibriCheck include Digital Health London, NHS Innovation Accelerator, Medica, JLabs, EIT Health Bridgehead and 7 more.
Who are FibriCheck's competitors?
Competitors of FibriCheck include AliveCor and 4 more.
What products does FibriCheck offer?
FibriCheck's products include FibriCheck B2C model (Essential and Premium) and 3 more.
Compare FibriCheck to Competitors
AliveCor focuses on the creation of machine learning techniques to enable proactive heart care. It offers artificial intelligence (AI) enabled, machine learning (ML) powered electrocardiogram (ECG) sensors that deliver heart data at any time. The company's digital tools help patients access, manage and share their data, and connect with cardiologists to understand and manage their heart health. It was formerly known as AliveUSA. AliveCor was founded in 2011 and is based in Mountain View, California.
Wellysis is a company focused on transforming healthcare from CURE to CARE, operating in the healthcare technology sector. The company offers a continuous ECG/EKG monitor that uses AI reporting to assist physicians in diagnosing in a faster, cheaper, and more convenient manner. Wellysis primarily serves the healthcare industry. It was founded in 2019 and is based in Seoul, South Korea.
Happitech develops a heart rhythm software development kit for Android and iPhone operating systems. The company offers algorithms allowing medical-grade vital signs monitoring directly through a smartphone. The company was founded in 2015 and is based in Rotterdam, Netherlands.
Mawi Heart is a digital health company that focuses on diagnosing and monitoring cardiac diseases. The company offers wearable medical devices and technology that provide advanced cardiac monitoring, designed with patient comfort and ease of use in mind. These devices are capable of scanning each heartbeat to detect critical rhythm abnormalities, providing continuous, uninterrupted data. It is based in Clearwater, Florida.
Qardio is a company that focuses on the development of innovative health monitoring devices, operating within the healthcare technology sector. The company's main offerings include smart blood pressure monitors, scales, ECG monitors, pulse oximeters, and thermometers, all designed to help consumers take charge of their health. Qardio primarily sells to the healthcare industry and individual consumers. Qardio was formerly known as HealthSynch, Inc.. It was founded in 2012 and is based in San Francisco, California.
Withings is a company that focuses on connected health technology in the healthcare industry. The company offers a range of products including smart scales, hybrid watches, blood pressure monitors, and sleep analyzers, all designed to provide medical-grade measurements at home. These products primarily cater to the healthcare and wellness sectors. It was founded in 2008 and is based in Issy-les-Moulineaux, France.